SEARCH

SEARCH BY CITATION

References

  • 1
    Rodriguez RA, Mendelson M, O'Hare AM, Hsu LC, Schoenfeld P. Determinants of survival among HIV-infected chronic dialysis patients. J Am Soc Nephrol 2003; 14: 13071313.
  • 2
    Martin-Carbonero L, Soriano V, Valencia E, Garcia-Samaniego J, Lopez M, Gonzalez-Lahoz J. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses 2001; 17: 14671471.
  • 3
    Rosenthal E, Poiree M, Pradier C et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 2003; 17: 18031809.
  • 4
    Halpern SD, Ubel PA, Caplan AL. Solid-organ transplantation in HIV-infected patients. N Engl J Med 2002; 347: 284287.
  • 5
    Dummer JS, Erb S, Breinig MK et al. Infection with human immunodeficiency virus in the Pittsburgh transplant population. A study of 583 donors and 1043 recipients, 1981–1986. Transplantation 1989; 47: 134140.
  • 6
    Poli F, Scalamogna M, Pizzi C, Mozzi F, Sirchia G. HIV infection in cadaveric renal allograft recipients in the North Italy Transplant Program. Transplantation 1989; 47: 724725.
  • 7
    Tzakis AG, Cooper MH, Dummer JS, Ragni M, Ward JW, Starzl TE. Transplantation in HIV+ patients. Transplantation 1990; 49: 354358.
  • 8
    Erice A, Rhame FS, Heussner RC, Dunn DL, Balfour HH, Jr. Human immunodeficiency virus infection in patients with solid-organ transplants: Report of five cases and review. Rev Infect Dis 1991; 13: 537547.
  • 9
    Bouscarat F, Samuel D, Simon F, Debat P, Bismuth H, Saimot AG. An observational study of 11 French liver transplant recipients infected with human immunodeficiency virus type 1. Clin Infect Dis 1994; 19: 854859.
  • 10
    Ragni MV, Dodson SF, Hunt SC, Bontempo FA, Fung JJ. Liver transplantation in a hemophilia patient with acquired immunodeficiency syndrome. Blood 1999; 93: 11131114.
  • 11
    Calabrese LH, Albrecht M, Young J et al. Successful cardiac transplantation in an HIV-1-infected patient with advanced disease. N Engl J Med 2003; 348: 23232328.
  • 12
    Neff GW, Bonham A, Tzakis AG et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl 2003; 9: 239247.
  • 13
    Ragni MV, Belle SH, Im K et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis 2003; 188: 14121420.
  • 14
    Stock PG, Roland ME, Carlson L et al. Kidney and liver transplantation in human immunodeficiency virus-infected patients: A pilot safety and efficacy study. Transplantation 2003; 76: 370375.
  • 15
    Abbott KC, Swanson SJ, Agodoa LY, Kimmel PL. Human immunodeficiency virus infection and kidney transplantation in the era of highly active antiretroviral therapy and modern immunosuppression. J Am Soc Nephrol 2004; 15: 16331639.
  • 16
    Kumar MS, Sierka DR, Damask AM et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int 2005; 67: 16221629.
  • 17
    Roland ME, Stock PG. Review of solid-organ transplantation in HIV-infected patients. Transplantation 2003; 75: 425429.
  • 18
    Margolis D, Heredia A, Gaywee J, Oldach D, Drusano G, Redfield R. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. J Acquir Immune Defic Syndr 1999; 21: 362370.
  • 19
    1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA). MMWR Recomm Rep 1999; 48: 159, 61–56.
  • 20
    Carter JT, Melcher ML, Carlson LL, Roland ME, Stock PG. Thymoglobulin-associated CD4+ T-cell depletion and infection risk in HIV-infected renal transplant recipients. Am J Transplant 2006; 6: 753760.
  • 21
    Terrault NA, Carter JT, Carlson L, Roland ME, Stock PG. Outcome of patients with hepatitis B virus and human immunodeficiency virus infections referred for liver transplantation. Liver Transpl 2006; 12: 801807.
  • 22
    Norris S, Taylor C, Muiesan P et al. Outcomes of liver transplantation in HIV-infected individuals: The impact of HCV and HBV infection. Liver Transpl 2004; 10: 12711278.
  • 23
    de Vera ME, Dvorchik I, Tom K et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant 2006; 6: 29832993.
  • 24
    Frassetto L, Baluom M, Jacobsen W et al. Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplantation 2005; 80: 1317.
  • 25
    Frassetto L TT, Aggarwal AM, Bucher P et al. Pharmacokinetic interactions between cyclosporine and protease inhibitors in HIV+ subjects. Drug Metab Pharmacokinet 2003; 18: 114120.
  • 26
    Frassetto LA, Baloum M, Roland ME, Carlson L, Stock P, Benet LZ. Two-year evaluation of the interactions between antiretroviral medication and cyclosporine in HIV+ liver and kidney transplant recipients. In: 10th Conference on Retroviruses and Opportunistic Infections; 2003 February 10–14, 2003; Boston , MA ; 2003.
  • 27
    Frassetto LA, Chen W, Kansal N, Levi M et al. Immunosuppressant adjustments of doses and dosing intervals in HIV-infected kidney and liver transplant patients. In: TransplantAsia 2004; 2004 December 1–4, 2004; Singapore ; 2004.
  • 28
    Vogel M, Voigt E, Schafer N et al. Orthotopic liver transplantation in human immunodeficiency virus (HIV)-positive patients: Outcome of 7 patients from the Bonn cohort. Liver Transpl 2005; 11: 15151521.